ESTUTC-5 New YorkLog in Sign up

CORT
Corcept Therapeutics Inc.
stockNASDAQ

At CloseNov 12, 2026 3:59:57 PM EST

73.71USD-1.100%(-0.82)847,070

Pre-marketNov 12, 2026 9:28:30 AM EST

74.75USD+0.295%(+0.22)

After-hoursNov 12, 2026 4:00:30 PM EST

73.71USD0.000%(0.00)

70.05Bid77.62Ask7.57Spread

CORT News

Day breaks

07:46 PM ESTCorcept Therapeutics former president Sean Maduck sells $2.05M in stock ·

Investing.com

02:05 PM ESTCorcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ... ·

GuruFocus

01:01 PM ESTCORT Reiterated by Piper Sandler -- Price Target Raised to $173 ·

GuruFocus

10:25 AM ESTCorcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript ·

The Motley Fool

07:11 AM ESTAt a glance: stocks gapping down premarket ·

Seeking Alpha

12:04 AM ESTCORT SWOT Analysis: Strong Revenue Growth Amidst Legal Challenges Revealed in 10-Q Filing ·

GuruFocus

11:00 PM ESTQ3 2026 Corcept Therapeutics Incorporated Earnings Call Transcript ·

GuruFocus

07:58 PM ESTCorcept Therapeutics (CORT) Posts Q3 Revenue of $340.5M, Maintains 2026 Guidance ·

GuruFocus

07:47 PM ESTCorcept targets $3B-$5B in Cushing’s revenue in 2030 as it awaits December 17 relacorilant FDA decision ·

Seeking Alpha

07:46 PM ESTCorcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript ·

Seeking Alpha

04:50 PM ESTCorcept Therapeutics falls on guidance despite earnings beat ·

Investing.com

04:13 PM ESTCorcept Therapeutics GAAP EPS of $1.01 beats by $0.22, revenue of $340.5M beats by $4.12M ·

Seeking Alpha

04:05 PM ESTCorcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update ·

Business Wire

10:00 AM ESTHere are the major earnings after the close Tuesday ·

Seeking Alpha

04:05 PM EDTCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call ·

Business Wire

08:00 AM EDTCorcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer ·

Business Wire

02:04 AM EDTCan Corcept Therapeutics Stock Rally 40% After This Dip? ·

Trefis

05:05 PM EDTCorcept Therapeutics plunges 20% on Genmab cancer data ·

Seeking Alpha

03:27 PM EDTGenmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer ·

Seeking Alpha

12:21 PM EDTWhy is Corcept Therapeutics stock tumbling today? ·

Investing.com